Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Envisioning a healthier every day, for every woman

By Sandy Lindsey

- PMLiVE

GSK’s Boostrix approved by FDA for use during pregnancy to prevent whooping cough in infants

4.2% of the cases of pertussis reported in the US in 2021 were in infants younger than six months

- PMLiVE

Biogen doses first patient with litifilimab in cutaneous lupus erythematosus study

The phase 2/3 study is expected to be conducted at approximately 238 sites worldwide

- PMLiVE

MHRA and NICE awarded £1.8m to explore regulation of digital mental health tools

The funding will go towards improving regulatory certainty and safety for mental health products

- PMLiVE

Merck’s sotatercept shows promise as pulmonary arterial hypertension add-on treatment in phase 3 trial

The study met its primary endpoint of a clinically meaningful improvement in six-minute walk distance

- PMLiVE

FDA approves scPharmaceuticals’ on-body infusor for congestive heart failure

The at-home device delivers the equivalent of what a patient would receive by way of IV

- PMLiVE

Agile strategy or strategy for ‘agile’?

By Maxine Smith and Melissa Dagless

- PMLiVE

WHO unveils AI-powered digital health worker, Florence 2.0

The chatbot builds on its previous version, which was used to tackle COVID-19 misinformation

- PMLiVE

Brainomix set to collaborate with NCIMI to assess AI-powered tech in lung cancer care

The partnership will compare automated evaluation versus observations of medical specialists

- PMLiVE

Alnylam’s RNAi therapeutic expanded by FDA in advanced primary hyperoxaluria type 1

A phase 3 trial showed Oxlumo treatment resulted in substantial reductions in plasma oxalate

- PMLiVE

New study links omega-3 intake in midlife to reduced dementia risk

Over 2,000 people who did not have dementia or stroke took part in the study

Infographic: Therapy Watch Psoriasis

Our PsO infographic offers an introduction to the real-world patient insights collected by our Therapy Watch PsO study.

Inizio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links